HTB homepage • Conference reports • Articles by subject • Subscribe 18 October 2019 Contents Editorial HTB 18 October 2019 online Conference reports IDWeek (2019), 2–6 October 2019, Washington DC HIV suppression and safety with ibalizumab at 48 weeks in expanded access Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available Switching from TDF to TAF linked to higher BMI and cardio risk Possible higher diabetes risk with raltegravir or PIs than NNRTIs Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives Over half of mostly black US HIV group has NAFLD – and many have NASH People taking more medications and women have higher fall risk in older HIV group No link between raltegravir and adverse birth outcomes in analysis in 2550 women PrEP linked to lower HIV incidence in US, independent of TasP Antiretrovirals Dual dolutegravir/lamivudine submitted to US FDA as switch option Treatment access UK contributes £1.4 billion towards Global Fund for 2020 to 2022 Global Fund raises US$14 billion for 2020 to 2022 Guidelines NHS England best practice in HIV prescribing and multidisciplinary teams HIV prevention and transmission US approves F/TAF for PrEP (Descovy): indication excludes risk from receptive vaginal sex Basic science and immunology Science journal retracts article linking CCR5 deletion to reduced life expectancy PDFs 18 October 2019 vol 20 no 12 HTB homepage • Conference reports • Articles by subject • Subscribe
